Purple Biotech Ltd (PPBT)
NASDAQ: PPBT · Real-Time Price · USD
1.050
-0.100 (-8.70%)
Oct 22, 2026, 4:00 PM EDT - Market closed
Purple Biotech Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
10
Market Cap
9.57M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Palatin Technologies | 13.19M |
| Ensysce Biosciences | 4.50M |
| BioLineRx | 1.39M |
| CytoMed Therapeutics | 609.73K |
| Lisata Therapeutics | 100.00K |
PPBT News
- 7 weeks ago - Why Is Purple Biotech (PPBT) Stock 42% Up Today? - TipRanks
- 7 weeks ago - Purple Biotech issued notice of allowance from USPTO - TheFly
- 7 weeks ago - New U.S. Patent Allowance Strengthens Protection for CAPTN-3 Modular Platform for Next-Generation Multispecific Antibodies - GlobeNewsWire
- 2 months ago - Purple Biotech price target lowered to $17 from $30 at H.C. Wainwright - TheFly
- 4 months ago - Purple Biotech presents new IM1240 data at EACR - TheFly
- 5 months ago - Purple Biotech files $200M mixed securities shelf - TheFly
- 5 months ago - Purple Biotech reports IM1240 demonstrates potent anti-tumor activity - TheFly
- 7 months ago - Purple Biotech announces collaboration with Converge Bio - TheFly